Developing microbiome-directed therapeutics for treating childhood undernutrition
Using multiomic methods, including SomaScan® proteomics, to judge clinical efficacy
Abstract
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
Learning objectives
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
- Understand evidence that impaired postnatal development of the gut microbiota is causally related to childhood undernutrition
- Understand how preclinical gnotobiotic animal models can be used to develop new microbiota-directed therapeutics
- Understand how multiomic methods, including SomaScan proteomics, can be used to judge the efficacy and mechanism of action of these therapeutics in clinical studies
Jeffrey Gordon, MD
Director, Edison Family Center for Genome Sciences and Systems Biology, Washington University
Michael J. Barratt, PhD
Executive Director, Center for Gut Microbiome and Nutrition Research, Washington University
Developing microbiome-directed therapeutics for treating childhood undernutrition
A webinar presented by Jeffrey Gordon, MD, and Michael J. Barratt, PhD
Request Information
More webinars
WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program
How SomaLogic Technologies can give your research programs an edge
WebinarA proteomics signature of NASH
There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.
WebinarEarly Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.